The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
|Videos|September 8, 2017
Dr. Esteva on Next-Generation Sequencing in Metastatic Breast Cancer
Author(s)Francisco J. Esteva, MD, PhD
Francisco J. Esteva, MD, PhD, medical oncologist, NYU Langone Medical Center, discusses next-generation sequencing in metastatic breast cancer.
Advertisement
Francisco J. Esteva, MD, PhD, medical oncologist, NYU Langone Medical Center, discusses next-generation sequencing in metastatic breast cancer.
Next-generation sequencing is not yet recommended as the standard of care by the FDA, though it is used at many large institutions.
Esteva says that the goal with this sequencing would allow treating physicians to direct their patients to appropriate clinical trials.
Advertisement
Related to this article
GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.
The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1–positive, metastatic triple-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026
5